Dose of Digital
- Who Responds To The Responders? Who Responds To The Responders?
As I thought it might, my last post about social media stirred quite a bit of discussion. As such, I thought it would be useful to perhaps dedicate another post as a means of both clarifying my position, and providing some counter-points t [...]
- Is It Time For Pharma To Give Up The Social Media Ghost? Is It Time For Pharma To Give Up The Social Media Ghost?
Social media has been a big focus for pharma marketers for a while now. By my count, at least 30-45% of ePharma’s agenda from the 2014 NY conference was focused on the subject, and there is a whole cottage industry of other conferences spe [...]
- Initial Impressions of Sphero 2.0: The Best and Worst of the Digital Age Initial Impressions of Sphero 2.0: The Best and Worst of the Digital Age
Last night I picked up a Sphero 2.0 from the Apple Store as I needed to test it out for a client project. After about 5 minutes I remarked to my wife that, “This is exactly what’s good and bad about my job. On the one hand, I get to play wi [...]
- A Deep Review Of My First 2 Months With Google Glass A Deep Review Of My First 2 Months With Google Glass
I’ve recently been adopted into the Google Glass explorer program. I debated whether or not to accept the invitation, but ultimately felt it probably would be a good idea, if for no other reason than there may be something unexpected that c [...]
- Friday Follow Ups Friday Follow Ups
Google Unveils Smart Contact Lens That Lets Diabetics Measure Their Glucose Levels – Unless it’s delivered via drones, 60 minutes won’t cover it. Tanning Bed Case Kills Phone Bacteria Overnight – I once worked for a guy who was [.
- 2014: The Year for FDA Guidance on Social Media 2014: The Year for FDA Guidance on Social Media
Many in the pharma industry have been anxiously awaiting social media guidance from FDA. Going all the way back to November 2009, FDA has repeatedly promised to provide more clarity around how it intends to regulate pharmaceutical promotion [...]
- FDA Draft Guidance Opens Up Social Options for Pharma FDA Draft Guidance Opens Up Social Options for Pharma
Whew! On Monday FDA quietly issued draft guidance titled, “Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics” In language that you an [...]
- Let's Give Our Friends at Med Ad News a Proper Send-off Let's Give Our Friends at Med Ad News a Proper Send-off
I was shocked and sad to learn that industry publication Med Ad News will no longer exist. The publisher recently sent this email to customers:December 13, 2013RE: Closure of MedAdNews/Pharmalive/Pharmalot/eKnowledgeBase/R&DDear Valued [...]
- What Every Pharma Procurement Group Needs: A "Rogue Agency" Roster What Every Pharma Procurement Group Needs: A "Rogue Agency" Roster
I read with interest the report in the June issue of MM&M, "Healthcare Marketers Trend Report 2013." The report benchmarks and analyzes topics that affect pharma marketers such as budgets, channel mix, perceived challenges, and more. On [...]
- Pharma's First Branded Facebook Ad? Pharma's First Branded Facebook Ad?
I was goofing around on Facebook last night when I noticed what looked suspiciously like a branded pharmaceutical advertisement:It was indeed an ad for Axert, a Janssen migraine treatment, and one click took me to the home page for Axert.c [...]
Eye on FDA
- Weekly Roundup – 4.18.14 Weekly Roundup – 4.18.14
There were audible gasps all over the Internet from people experiencing yet more snow this week – the week of Easter break for many. Freeze warnings here threatened my young herbs planted only a few days before over a warm … Co [...]
- Release of CMS Medicare Payment Data a Sunshine Dress Rehearsal Release of CMS Medicare Payment Data a Sunshine Dress Rehearsal
There were two major healthcare stories last week. One involved the announcement that Health and Human Services Secretary Kathleen Sebelius would be leaving and the nomination by President Obama of Office of Management and Budget Director [...]
- Weekly Roundup 4.11.14 Weekly Roundup 4.11.14
A few weeks ago it was snowing. Today, a walk around the neighborhood yields views of piles of mulch near driveways ready to be loaded into wheelbarrows and spread into the garden beds. Bags of topsoil are lined up. Grass … Continu [...]
- Sunset on the ROI of Social Media and Pharma Discussion Sunset on the ROI of Social Media and Pharma Discussion
While many pharma companies have developed a wide and deep footprint in social media, many others have not. When exploring the issue of whether or not to involve a brand, there are several questions to consider. Some are very important [...]
- Weekly Roundup 4.4.14 Weekly Roundup 4.4.14
Dumbfounded by another week packed with business travel. It was a week that truly involved planes, trains and automobiles. I wish I could say that it will be a while before I am once again in an airport, but it … Continue reading [...]
Pharma Marketing Blog
- What Pharma Can Learn from the CPG Industry About Social Media: If You "Like" Me, You Can't Sue Me! What Pharma Can Learn from the CPG Industry About Social Media: If You "Like" Me, You Can't Sue Me!
The social networking savvy of consumer packaged goods (CPG) industry is often cited by pharma marketing consultants as something the pharmaceutical industry should emulate.Here's what one interactive agency -- picked at random via a Go [...]
- Digital Health Coalition Urges FDA to Launch a Social Media "Laboratory" to Ensure Adequate Guidance Progress Digital Health Coalition Urges FDA to Launch a Social Media "Laboratory" to Ensure Adequate Guidance Progress
In comments submitted to the FDA regarding recent social media guidance (read "FDA Publishes First Piece of Long-Awaited Social Media Guidance" for background), the Digital Health Coalition (DHC) -- comprised mostly of pharma comp [...]
- BIO Mimics PhRMA's Comments to FDA Regarding Recent SM Guidance But Is More Polite About It BIO Mimics PhRMA's Comments to FDA Regarding Recent SM Guidance But Is More Polite About It
In its opening remarks in comments submitted to the FDA regarding recent Draft Guidance ("Guidance for Industry: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human a [...]
- More Free Rx Drug Samples, More Branded Drug Prescriptions. Duh! More Free Rx Drug Samples, More Branded Drug Prescriptions. Duh!
According to a study published today in JAMA Dermatology, branded and branded generic drugs (products that have novel dosage forms of off-patent products or use a trade name for a molecule that is off patent) accounted for 79 percent of the [...]
- PhRMA Questions Legality of FDA's Recent Social Media Guidance PhRMA Questions Legality of FDA's Recent Social Media Guidance
The FDA received about 20 comments from representatives of the pharmaceutical industry, In my last post, I summarized the comments submitted by Novartis (see "Delete This and Delete That, Says Novartis to FDA Regarding Recent Social Me [...]
- The List gets longer and longer The List gets longer and longer
- And they try to tell you Big Pharma's Misdeeds Are All in the Past! And they try to tell you Big Pharma's Misdeeds Are All in the Past!
- Doctor Richard Saul: ADHD Does Not Exist Doctor Richard Saul: ADHD Does Not Exist
- GSK Poland - Shelley Jofre writes in the BMJ GSK Poland - Shelley Jofre writes in the BMJ
- Panorama - Who's Paying Your Doctor? Panorama - Who's Paying Your Doctor?
- Compounder Strikes Preliminary $100M Deal Over Meningitis Outbreak Compounder Strikes Preliminary $100M Deal Over Meningitis Outbreak
More than a year after an outbreak of fungal meningitis was traced to the New England Compounding Center and caused the worst public health crisis in the US in decades, the owners, operators and insurers of the bankrupt com [...]
- What Competition? Actelion Loses Case Over Stifling A Rival Drug What Competition? Actelion Loses Case Over Stifling A Rival Drug
For the second time this year, Actelion has been tagged for questionable behavior toward rivals. In the latest instance, a California state court judge has upheld a $407 million jury award that was made after the drugmaker [...]
- The Affordable Care Act Gives Drugmakers A Boost: CMS The Affordable Care Act Gives Drugmakers A Boost: CMS
What hath the Affordable Care Act wrought? For drugmakers, there looks to be a big boost in spending on prescription medicines. Projected spending is forecast to grow 5.2 percent next year, compared with 0.6 percent growth [...]
- Will FDA Widen Use For The Vasecpa Fish Oil Pill, After All? Will FDA Widen Use For The Vasecpa Fish Oil Pill, After All?
In a surprising development that has revived intense speculation over the fate of Amarin, the FDA has delayed any decision about whether to widen an indication for the Vascepa prescription fish oil pill. The move was expect [...]
- Pharmalot... Pharmalittle... Good Morning Pharmalot... Pharmalittle... Good Morning
Good morning, everyone, and how are you today? We hope the weekend was relaxing and invigorating, especially for those of you who are resuming something resembling the usual routine this morning. Of course, we recognize thi [...]
The IN VIVO Blog
- Deals of the Week Takes Stock in M&A Deals of the Week Takes Stock in M&A
Here at Deals of the Week, we don’t often take note explicitly of buyouts outside the biopharma sphere. But one well-publicized tech deal last month piqued our interest – and it parallels another recent pharma deal in a way we found curious [...]
- What Is the Buoyant Biotech IPO Scene Doing to Private Biotech M&A Trends? FOTF Says: Not Much What Is the Buoyant Biotech IPO Scene Doing to Private Biotech M&A Trends? FOTF Says: Not Much
Despite a slight slowdown, there's considerable cash already sloshing around the biotech IPO space. There's (still!) plenty more stacked up in investor suitcases from California to the New York Island just waiting to back anything with a pu [...]
- Stakeholders in Consumer Genomics, Read This Stakeholders in Consumer Genomics, Read This
Noting a flurry of recent commentaries in peer-review journals, our February Science Matters column in START-UP (link here, free access) discussed how the personal genomics company 23andMe has accelerated the consumer genomics debate throug [...]
- DOTW Keeps Tabs As Tax Trimming Fuels Deals DOTW Keeps Tabs As Tax Trimming Fuels Deals
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they [...]
- Deals Of The Week: Novartis Places Bid To Dominate In Cancer Deals Of The Week: Novartis Places Bid To Dominate In Cancer
While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded portfolio via its $25 billion purchase of Forest Laboratories, the deal that could have major implications fo [...]